Retatrutide is the new triple-agonist weight loss drug from Eli Lilly that showed an average 28.7% body weight loss in Phase 3 trials — outperforming Ozempic and Mounjaro. It’s not yet available in the UK, but here’s everything you need to know, plus the supplements that support any weight loss journey.